Antifungal susceptibility of emerging yeast pathogens

被引:31
作者
García-Martos, P [1 ]
Domínguez, I [1 ]
Marín, P [1 ]
García-Agudo, R [1 ]
Mira, SAYJ [1 ]
机构
[1] Hosp Univ Puerta Mar, Cadiz, Spain
来源
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2001年 / 19卷 / 06期
关键词
yeasts; antifungal agents; Candida; fluconazole;
D O I
10.1016/S0213-005X(01)72630-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BACKGROUND. To study the antifungal susceptibility of emerging yeast pathogens to know their possible resistance under the need of applying a treatment. MATERIAL AND METHODS. We investigated the in vitro susceptibility of 69 yeast strains isolates of clinical samples, belonging to 24 different species, to amphotericin B, fluconazole, itraconazole, ketoconazole and 5-fluorocytosine. RESULTS. Only 9 species showed susceptibility to all antifungal agents: Candida famata, C. guillermondii, C. holmii, C. kefyr, C. pelliculosa, C. rugosa, C. utilis, C. zeylanoides y Trichosporon cutaneum; the rest of them presented resistance to some antifungal agent. C. haemulonii; Pichia farinosa and Trichosporon mucoides were resistant to amphotericin B; C. haemulonii, C. inconspicua, C. lusitaniae, C. norvegensis, C. pintolepesii, C. valida, P. ohmeri, Rhodotorula glutinis, R. minuta, R. mucilaginosa and Saccharomyces cerevisiae were resistant to azoles; Blastoschizomyces capitatus and C. lipolytica were resistant to 5-fluorocytosine. CONCLUSIONS. The resistance of emerging yeast pathogens to amphotericin B and 5-fluorocytosine is low, while resistance to azoles is significative, especially to fluconazole (36%). Many of this yeasts present problems of intrinsic resistance. In yeast infections, the correct identification of species and the study of the in vitro susceptibility is important in order to choose the most adequate antifungal treatment.
引用
收藏
页码:249 / 256
页数:10
相关论文
共 109 条
[11]   Pichia ohmeri fungemia [J].
Bergman, MM ;
Gagnon, D ;
Doern, GV .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 30 (03) :229-231
[12]   TRANSIENT FUNGEMIA AND CANDIDA ARTHRITIS DUE TO CANDIDA-ZEYLANOIDES [J].
BISBE, J ;
VILARDELL, J ;
VALLS, M ;
MORENO, A ;
BRANCOS, M ;
ANDREU, J .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1987, 6 (06) :668-669
[13]   RESOLUTIVE CANDIDA-UTILIS FUNGEMIA IN A NONNEUTROPENIC PATIENT [J].
BOUGNOUX, ME ;
GUEHO, E ;
POTOCKA, AC .
JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (06) :1644-1645
[14]   YEAST IN BLOOD CULTURES - EVALUATION OF FACTORS INFLUENCING OUTCOME [J].
BRYCE, EA ;
ROBERTS, FJ ;
SEKHON, AS ;
COLDMAN, AJ .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1992, 15 (03) :233-237
[15]  
Burgess N A, 1992, HPB Surg, V5, P79, DOI 10.1155/1992/90415
[16]  
CARCELLER A, 1991, Revista Iberoamericana de Micologia, V8, P70
[17]   Candida famata fungemia in a surgical patient successfully treated with fluconazole [J].
Carrega, G ;
Riccio, G ;
Santoriello, L ;
Pasqualini, M ;
Pellicci, R .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1997, 16 (09) :698-699
[18]  
Carrillo-Munoz A J, 1999, Rev Esp Quimioter, V12, P126
[19]   SACCHAROMYCES-CEREVISIAE EMPYEMA IN A PATIENT WITH ESOPHAGO-PLEURAL FISTULA COMPLICATING VARICEAL SCLEROTHERAPY [J].
CHERTOW, GM ;
MARCANTONIO, ER ;
WELLS, RG .
CHEST, 1991, 99 (06) :1518-1519
[20]  
Cheung MY, 1999, J FORMOS MED ASSOC, V98, P787